Peptides were mainstream all along

The online peptide world often presents peptides as a secret that doctors do not want you to know about. The Complete Guide to Peptides accidentally proves the opposite.

Look through its encyclopedia and you find, alongside the research compounds, a list of long-established prescription medicines: ACTH, calcitonin, oxytocin, triptorelin, liraglutide, semaglutide, tirzepatide and tesamorelin. Add insulin, which the book mentions only in passing, and you have some of the most important drugs in modern medicine.

Peptides are not fringe. They have been central to medicine for a century. Seeing these established drugs next to the experimental ones is one of the most useful things this book offers, because it shows you what "proven" looks like.

ACTH: the stress hormone's messenger

The book describes ACTH (adrenocorticotropic hormone) accurately. It is made by the pituitary gland and tells the adrenal glands to release cortisol. It sits at the centre of the body's stress response system, the HPA axis.

Its main established uses are diagnostic, testing whether the adrenal glands respond properly (for example in suspected Addison's disease), and, in some formulations, treating specific conditions such as certain flares of multiple sclerosis and infantile spasms.

The book's safety section is sensible here: side effects come from raised cortisol, including weight gain, mood changes, fluid retention and high blood pressure, and prolonged use can cause Cushing's syndrome.

One claim does not hold up: the book lists "adrenal fatigue" as a use. Adrenal fatigue is not a recognised medical diagnosis. Giving ACTH to someone with normal adrenal glands to treat it would push cortisol up for no established benefit and real risk.

Calcitonin: the bone hormone

Calcitonin is a peptide hormone from the thyroid gland that reduces the activity of osteoclasts, the cells that break down bone. The book lists its uses in osteoporosis, Paget's disease and high blood calcium, and notes a nasal spray form at 200 IU daily for osteoporosis.

What the book does not mention is an important piece of history. In 2012, European regulators reviewed calcitonin and found a small increased risk of cancer with long-term use. As a result, its use was restricted to short-term treatment in specific situations, and the nasal spray for osteoporosis was withdrawn in Europe. Other, more effective osteoporosis drugs have largely replaced it.

It is a good example of how approved medicines keep being watched after approval, and how the picture can change. That kind of long-term surveillance simply does not exist for research peptides.

Oxytocin: much more than the "love hormone"

The book's entry covers oxytocin's roles in childbirth, breastfeeding and social bonding. Its established medical uses are in labour induction and preventing bleeding after birth. That use is critical: postpartum haemorrhage is a leading cause of maternal death worldwide, and oxytocin is on the World Health Organization's list of essential medicines for exactly that reason.

The book also describes the research into intranasal oxytocin for anxiety, autism and social difficulties. That research is real but the results have been inconsistent. It notes one correct and important caution: overuse in pregnancy can cause excessive uterine contractions.

Triptorelin: the drug that works by overstimulating

Triptorelin is one of the most counterintuitive drugs in the book, and the book explains it well.

It mimics GnRH, the brain hormone that tells the pituitary to release LH and FSH. When you first give it, sex hormone levels rise. But the body's natural GnRH comes in pulses. A constant signal causes the pituitary's receptors to switch off. After a week or two, LH, FSH, testosterone and oestrogen all fall to very low levels.

So a drug that mimics a stimulating hormone ends up suppressing the whole system. This is used deliberately to treat hormone-sensitive prostate cancer, endometriosis, fibroids and early puberty, and to control ovulation during IVF.

The book correctly lists the main side effects: hot flushes, mood changes, and bone loss with prolonged use.

Tesamorelin and the GLP-1 drugs

Part 3 covered the GLP-1 drug family. Tesamorelin, a GHRH analogue, is also approved, specifically to reduce excess visceral fat in people with HIV-associated lipodystrophy. The book correctly notes the need to monitor IGF-1 and caution in anyone with a cancer history.

What these entries teach

Put the approved medicines side by side and a pattern emerges.

  • They have specific approved uses, often narrower than the enthusiasm around them suggests.
  • Their doses are precise and come from trials, like liraglutide's 0.6 mg to 3 mg daily schedule or triptorelin's 3.75 mg monthly depot.
  • Their side effects are documented in detail, including uncomfortable ones, because they have been given to thousands of people and watched.
  • Their safety picture can change as more data comes in, as calcitonin showed.

Now compare that with the entries for research compounds in the same book. Uses are broad and sweeping. Side effects are usually listed as mild injection site irritation. Long-term safety is described as "generally well tolerated".

The difference is not that research peptides are necessarily more dangerous. It is that nobody has looked closely enough to know.

The takeaway

The most valuable lesson in this book might be one it never states directly: peptide medicine is already here, it is already mainstream, and it already has a system for proving what works. Every approved drug in these pages went through it.

When someone tells you a peptide is so good that doctors are ignoring it, ask why it has not gone through the same process as oxytocin, calcitonin and semaglutide. Sometimes the answer is money or patents. Often it is that the evidence is not there yet. Either way, it is the right question.

This series reviews a consumer book, not a clinical guideline. Many compounds it discusses are not approved for human use in most countries. Nothing here is medical advice or a recommendation to use any substance. Speak to a qualified clinician before starting anything.